Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cipriani A, Furukwa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. . Lancet 2018;391:7 de abril. [Ref.ID 102476]
3.Tiene citas relacionadas Cita con resumen
Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388:881-90. [Ref.ID 100612]
4.Tiene citas relacionadas
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62. [Ref.ID 96106]
5.Tiene citas relacionadas Cita con resumen
Leucht S, Tardy M, Komosa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71. [Ref.ID 93128]
6.Tiene citas relacionadas Cita con resumen
Leucht S, Kissling W, Engel RR, Davis JM. Are new drugs for schizophrenia better than old ones? Authors' reply. Lancet 2009;373:1249-50. [Ref.ID 85617]
7.Tiene citas relacionadas Cita con resumen
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41. [Ref.ID 84954]
8.
Hamann J, Kolbe G, Cohen R, Leucht S, Kissling W. How do psychiatrists choose among different antipsychotics?. Eur J Clin Pharmacol 2005;61:851-4. [Ref.ID 75702]
9.Tiene citas relacionadas Cita con resumen
Leucht S, Wahlbeck K, Engel R, Hamann J, Kissling W. New generation versus conventional antipsychotics. Authors' reply. Lancet 2003;362:404. [Ref.ID 67060]
10. Cita con resumen
Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9. [Ref.ID 66022]
Seleccionar todas
 
 1 a 10 de 10